Get the Stockscreener App
15.46
1.24%
0.19
After Hours:
15.25
-0.21
-1.36%
Urogen Pharma Ltd stock is traded at $15.46, with a volume of 1.35M.
It is up +1.24% in the last 24 hours and up +5.53% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$15.27
Open:
$15.4
24h Volume:
1.35M
Relative Volume:
0.47
Market Cap:
$714.27M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-4.2125
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+6.69%
1M Performance:
+5.53%
6M Performance:
+51.72%
1Y Performance:
-2.09%
1-Day Range:
$15.04
$15.66
1-Week Range:
$13.79
$15.80
52-Week Range:
$3.42
$17.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
15.46 | 668.10M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.
UroGen Pharma Ltd. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
What analysts say about UroGen Pharma Ltd. stockTremendous growth potential - Autocar Professional
UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq
UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus
UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia
UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative
UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire
Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan
What drives UroGen Pharma Ltd. stock priceBreakthrough financial growth - Autocar Professional
Is UroGen Pharma Ltd. a good long term investmentFree Stock Selection - PrintWeekIndia
2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse
UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Bets Big On Gel-Based Cancer Treatments - Finimize
URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire
2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View
UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire
What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru
2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse
What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire
Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire
UroGen bladder cancer drug mitomycin wins FDA approval - MSN
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛
UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa
UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress - Investing.com India
UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer - Yahoo Finance
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st
URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus
UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com India
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock New - GuruFocus
UroGen completes enrollment in phase 3 bladder cancer trial - Investing.com
UroGen Pharma Completes Patient Enrollment in Phase 3 UTOPIA Trial for UGN-103 in Bladder Cancer Treatment - Nasdaq
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen ... - Bluefield Daily Telegraph
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):